In Vivo Bioequivalence Study of Drug: An Analysis of Registration in Vietnam Period 2012-2022

After more than 10 years of implementation in vivo Bioequivalence study, there are 835 drugs licensed to manufacture Vietnam, accounting for 77.89% circulate on the Vietnamese pharmaceutical market period 2012-2022, a worthwhile result. An achievement development In study recent is that state management agency (Ministry Health) has increased required active ingredients submit bioequivalence reports drug registration Vietnam from 12 26 ingredients. next few years, this number will gradually increase. Therefore, Government should introduce promotion, development, and preferential policies enterprises invest these This paper aims at providing with an overview information current license Vietnam; supporting studies practice.
 Keywords: Bioequivalence, BABE, BE, Regulations, Registration.